Parvinder K. Aley

University of Oxford - Centre for Vaccinology and Tropical Medicine

Oxford

United Kingdom

SCHOLARLY PAPERS

8

DOWNLOADS
Rank 184

SSRN RANKINGS

Top 184

in Total Papers Downloads

97,682

SSRN CITATIONS

4

CROSSREF CITATIONS

3

Scholarly Papers (8)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Federal University of Sao Paulo, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of the Witwatersrand, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Bristol - Cellular and Molecular Medicine, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 51,930 (34)
Citation 3

Abstract:

Loading...

2.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Number of pages: 45 Posted: 25 Jun 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Public Health England Colindale, Government of the United Kingdom - Public Health Scotland, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University Hospitals Birmingham NHS Foundation Trust, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Bristol - Cellular and Molecular Medicine, University of Oxford - The Jenner Institute, Government of the United Kingdom - North Bristol NHS Trust, NIHR UCLH Clinical Research Facility, Public Health England - Immunisation, Hepatitis, and Blood Safety Department, University of Southampton - University Hospital Southampton NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Imperial College London - National Heart & Lung Institute, University of Nottingham - Division of Epidemiology and Public Health, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 25,087 (135)
Citation 4

Abstract:

Loading...

3.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Oxford Vaccine Group, University of Bristol - Cellular and Molecular Medicine, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Cambridge, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent and Independent
Downloads 10,229 (714)
Citation 25

Abstract:

Loading...

4.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Number of pages: 35 Posted: 28 Jun 2021
University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute and Independent
Downloads 8,423 (991)
Citation 10

Abstract:

Loading...

5.

Randomized Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine

Number of pages: 32 Posted: 30 Dec 2021
University of Siena - Institute of Global Health, Federal University of Sao Paulo, Grid Europe Consult, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine and affiliation not provided to SSRN
Downloads 982 (33,041)

Abstract:

Loading...

Randomized, Immunogenicity, Safety, study, heterologous, homologous, COVID-19, booster, vaccination, two dose, three dose, third, second, Coronavac, Sinovac, SARS-CoV-2, schedule, coronavirus, pandemic, Oxford, Brazil, Ministry of Health, protection

6.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Imperial College London - Section of Virology, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 612 (62,330)
Citation 2

Abstract:

Loading...

7.

Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)

Number of pages: 43 Posted: 20 Dec 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of London - Institute of Infection and Immunity, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 405 (102,742)

Abstract:

Loading...

ChAdOx1 nCoV-19, AZD1222, Safety, Immunogenicity, Adolescent, COVID-19

8.

Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

Number of pages: 30 Posted: 28 Jul 2022
University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, National Institute For Communicable Diseases Of South Africa - Division of Public Health Surveillance and Response, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Faculty of Health Sciences, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), Setshaba Research Centre, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Setshaba Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Soweto Clinical Trials Centre, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of the Witwatersrand, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, Setshaba Research Centre, National Institute for Communicable Diseases of the National Health Laboratory Service, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of the Witwatersrand, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa and University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit
Downloads 14 (753,173)

Abstract:

Loading...

COVID-19, AZD1222, immunogenicity, durability of protection